Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 13;8(12):2203.
doi: 10.3390/jcm8122203.

Hyperprolactinaemia

Irene Samperi  1   2   3 , Kirstie Lithgow  1   2   3 , Niki Karavitaki  1   2   3
Affiliations
Review

Hyperprolactinaemia

Irene Samperi et al. J Clin Med. .

Abstract

Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It relates with various aetiologies (physiological, pharmacological, pathological), the clarification of which requires careful history taking and clinical assessment. Analytical issues (presence of macroprolactin or of the hook effect) need to be taken into account when interpreting the prolactin values. Medications and sellar/parasellar masses (prolactin secreting or acting through "stalk effect") are the most common causes of pathological hyperprolactinaemia. Hypogonadism and galactorrhoea are well-recognized manifestations of prolactin excess, although its implications on bone health, metabolism and immune system are also expanding. Treatment mainly aims at restoration and maintenance of normal gonadal function/fertility, and prevention of osteoporosis; further specific management strategies depend on the underlying cause. In this review, we provide an update on the diagnostic and management approaches for the patient with hyperprolactinaemia and on the current data looking at the impact of high prolactin on metabolism, cardiovascular and immune systems.

Keywords: antipsychotics; dopamine agonists; hyperprolactinaemia; hypogonadism; prolactin; prolactinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Proposed algorithm for investigating hyperprolactinaemia.
See this image and copyright information in PMC

References

    1. Tucker H.A. Hormones, mammary growth, and lactation: A 41-year perspective. J. Dairy Sci. 2000;83:874–884. doi: 10.3168/jds.S0022-0302(00)74951-4. - DOI - PubMed
    1. Trott J.F., Vonderhaar B.K., Hovey R.C. Historical perspectives of prolactin and growth hormone as mammogens, lactogens and galactagogues—Agog for the future! J. Mammary Gland Biol. Neoplasia. 2008;13:3–11. doi: 10.1007/s10911-008-9064-x. - DOI - PubMed
    1. Riddle O., Bates R.W., Dykshorn S.W. The preparation, identification and assay of prolactin—A hormone of the anterior pituitary. Am. J. Physiol. Leg. Content. 1933;105:191–216. doi: 10.1152/ajplegacy.1933.105.1.191. - DOI
    1. Friesen H., Guyda H., Hardy J. Biosynthesis of Human Growth Hormone and Prolactin. J. Clin. Endocrinol. Metab. 1970;31:611–624. doi: 10.1210/jcem-31-6-611. - DOI - PubMed
    1. Lewis U.J., Singh R.N., Seavey B.K. Human prolactin: Isolation and some properties. Biochem. Biophys. Res. Commun. 1971;44:1169–1176. doi: 10.1016/S0006-291X(71)80209-7. - DOI - PubMed

LinkOut - more resources